NIH's $5M REACH Hubs Forecast Maps Where the Next Biomedical Startups Will Form

For SBIR/STTR founders who spun their first startup out of a university lab, NIH just flagged where the next biomedical companies will be born: on June 25, 2026 it posted RFA-OD-27-009, a $5 million plan to seed five new Research Evaluation and Commercialization Hubs (REACH), per grants.gov.

The notice is a forecast, not an open solicitation. NIH is not taking applications yet. But the posting matters for small-business founders for a reason that is easy to miss if you only watch the SBIR and STTR funding lines: REACH is the upstream machine that manufactures the companies that later compete for those awards. If you want to understand where biomedical startups come from over the next four years, this is the map.

What RFA-OD-27-009 actually funds

The forecast for RFA-OD-27-009 lives at grants.gov, posted June 25, 2026 by the NIH SEED (Small business Education and Entrepreneurial Development) Office under CFDA 93.310, Trans-NIH Research Support. The headline numbers: NIH plans to fund five new academic entrepreneurship hubs, with an estimated $5 million in program funding to launch them. That tracks the prior round's structure, in which each hub received roughly $1 million per year for four years.

A REACH hub is not a research grant in the ordinary sense. NIH gives a qualifying institution money to build a standing engine that does four things, in the agency's own framing: identify the most promising academic biomedical technologies; fund early product-development work such as feasibility studies, prototypes, and proof-of-concept studies; provide access to expertise in science, regulation, reimbursement, business, law, and project management; and offer entrepreneurship training and hands-on commercialization experience. In plainer terms, a hub is a venture studio bolted onto a university, with NIH as anchor seed investor.

The timeline in the forecast is concrete enough to plan against. NIH estimates it will publish the full Notice of Funding Opportunity around September 30, 2026, with applications due roughly November 30, 2026, awards by April 30, 2027, and projects starting June 1, 2027. The agency was explicit about why it is posting now, months ahead of the real NOFO: "Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects." Translation — the institutions that win these are already assembling their consortia this summer.

Why an institutional award belongs on a founder's radar

Read the eligibility language carefully, because it is the most founder-relevant detail in the document. The primary applicant must be "a university or other research institution that participates in the NIH STTR program," and NIH defines participation precisely: the institution must have "been a formal partner to a small business on an STTR award."

Sit with that for a second. NIH is rationing access to a $5 million commercialization program by whether an institution has already done STTR deals with small businesses. The agency is rewarding universities that have a track record of partnering with startups — which is to say, the eligibility criterion itself is a signal of which campuses are friendly to founders. If you are an SBIR/STTR entrepreneur deciding where to license technology, recruit a co-founder, or place a research subcontract, the roster of institutions that pursue and win REACH hubs is a shortlist of the most commercialization-literate research environments in the country.

The hubs do not write you an SBIR check — those still come through the agencies' own Phase I and Phase II mechanisms. What a hub does is fund and de-risk the proof-of-concept work that happens before a company is fundable, and then train the scientists doing it to think like operators. The previous generation of this program shows the throughput. Across REACH and its predecessor NCAI hubs, NIH reports the network supported 269 research-and-development projects, trained more than 2,200 scientists in entrepreneurship, and helped form 59 spin-out small businesses. Those 59 companies are exactly the cohort that shows up two and three years later as SBIR and STTR applicants. The hub is the feeder; the small-business awards are the next leg.

The Phase 0 connection and why the statute matters

There is a policy thread in RFA-OD-27-009 that SBIR/STTR founders should not skip. The forecast states that the five awardees "will build on lessons learned from previous REACH hubs and support the goals of the Phase 0 Proof of Concept Partnership pilot program, as authorized by the 2011 SBIR/STTR Reauthorization Act (P.L. 112-81 Section 5127) and extended through fiscal year 2031 under the Small Business Innovation and Economic Security Act (P.L. 119-83)."

That citation is doing real work. Phase 0 is the conceptual ancestor of REACH — the idea that the government should fund the gap between a basic-science discovery and a company that can credibly apply for an SBIR Phase I award. The reauthorization detail is the part to highlight: the same law that extended the federal SBIR and STTR programs also extended the Proof of Concept authority through FY2031. For founders who have spent the last few years watching SBIR reauthorization fights with their hearts in their throats, REACH is a tangible sign that the proof-of-concept infrastructure underneath the small-business programs has runway through the end of the decade. NIH is not standing up a four-year, $5 million hub program if it expects the legal scaffolding to vanish in 2026.

NIH also frames the hubs against broader R&D priorities that read like a founder's pitch deck: "preparing the 21st-century workforce, moving technologies from the lab to the marketplace, strengthening partnerships among government, industry, and academia, and addressing local health needs, particularly in medically underserved and/or rural areas." The last clause is worth flagging for founders outside the coastal biotech corridors. The prior round of hubs reached innovators at more than 75 institutions across 12 states. Geography is part of the design, and a hub in your region changes the local odds of a deep-tech medical startup ever getting off the bench.

Public-private matching is the quiet requirement

One more line deserves attention because it shapes who actually wins and what the hubs will look like: NIH writes that "public-private partnerships and non-federal matching funding will be important to the program's success." REACH money is meant to be catalytic, not total. Winning institutions are expected to bring industry partners, foundation dollars, and often state economic-development funds to the table.

For a founder, that matching requirement is a feature. It means the hubs that get funded will have committed corporate and philanthropic partners attached — exactly the kind of non-dilutive capital, advisory bench, and pilot-customer relationships an early biomedical company needs and rarely has the network to assemble alone. If you are evaluating which university ecosystem to plant a company in over the next 18 months, ask whether the institution is assembling a REACH application, and who its matching partners are. That answer tells you more about your future support structure than any glossy tech-transfer brochure.

How to position before the September NOFO

There is no application for a founder to file here — REACH money flows to institutions, not companies. But there is a clear sequence of moves between now and the estimated September 30, 2026 NOFO. First, identify whether your home institution, alma mater, or prospective licensing partner has held a REACH or NCAI hub before, or is eligible by virtue of past STTR partnerships; those are the campuses most likely to compete and win again. Second, get on the radar of the relevant tech-transfer or innovation office now, while consortia are forming — hubs need pipeline projects and founder talent, and "responsive projects" is NIH's own phrasing for what they are recruiting this summer. Third, line up your direct SBIR/STTR strategy in parallel, because a hub accelerates you toward those awards rather than replacing them. Questions on the program itself go to the NIH SEED office at nihreach@nih.gov.

The faster lever you can pull today is your own agency pipeline. While the hubs take shape, map the SBIR and STTR solicitations that fund the science your future hub would help commercialize. You can search active SBIR and STTR solicitations across federal agencies on Granted, and browse the Granted blog for deeper playbooks on building a federal non-dilutive funding stack. REACH decides where the next biomedical companies incubate; your SBIR strategy decides whether yours is one of them.